Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 22;63(5):420-424.
doi: 10.1002/jmd2.12318. eCollection 2022 Sep.

N-acetylglutamate synthase deficiency with associated 3-methylglutaconic aciduria: A case report

Affiliations
Case Reports

N-acetylglutamate synthase deficiency with associated 3-methylglutaconic aciduria: A case report

Arthavan Selvanathan et al. JIMD Rep. .

Abstract

N-acetylglutamate synthase (NAGS) deficiency is a rare autosomal recessive disorder, which results in the inability to activate the key urea cycle enzyme, carbamoylphosphate synthetase 1 (CPS1). Patients often suffer life-threatening episodes of hyperammonaemia, both in the neonatal period and also at subsequent times of catabolic stress. Because NAGS generates the cofactor for CPS1, these two disorders are difficult to distinguish biochemically. However, there have now been numerous case reports of 3-methylglutaconic aciduria (3-MGA), a marker seen in mitochondrial disorders, occurring in CPS1 deficiency. Previously, this had not been reported in NAGS deficiency. We report a four-day-old neonate who was noted to have 3-MGA at the time of significant hyperammonaemia and lactic acidosis. Low plasma citrulline and borderline orotic aciduria were additional findings that suggested a proximal urea cycle disorder. Subsequent molecular testing identified bi-allelic pathogenic variants in NAGS. The 3-MGA was present at the time of persistent lactic acidosis, but improved with normalization of serum lactate, suggesting that it may reflect secondary mitochondrial dysfunction. NAGS deficiency should therefore also be considered in patients with hyperammonaemia and 3-MGA. Studies in larger numbers of patients are required to determine whether it could be a biomarker for severe decompensations.

Keywords: 3‐methylglutaconic aciduria; N‐acetylglutamate synthase deficiency; Urea cycle disorder; mitochondrial dysfunction.

PubMed Disclaimer

Conflict of interest statement

We declare no conflicts of interest.

References

    1. Mew NA, Caldovic L. N‐acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. Appl Clin Genet. 2011;4:127‐135. doi:10.2147/TACG.S12702 - DOI - PMC - PubMed
    1. Kenneson A, Singh RH. Presentation and management of N‐acetylglutamate synthase deficiency: a review of the literature. Orphanet J Rare Dis. 2020;15(1):279. doi:10.1186/s13023-020-01560-z - DOI - PMC - PubMed
    1. Rokicki D, Pajdowska M, Trubicka J, et al. 3‐Methylglutaconic aciduria, a frequent but underrecognized finding in carbamoyl phosphate synthetase I deficiency. Clin Chim Acta. 2017;471:95‐100. doi:10.1016/j.cca.2017.05.023 - DOI - PubMed
    1. Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192‐1230. doi:10.1002/jimd.12100 - DOI - PubMed
    1. Wortmann SB, Kluijtmans LAJ, Rodenburg RJ, et al. 3‐Methylglutaconic aciduria—lessons from 50 genes and 977 patients. J Inherit Metab Dis. 2013;36(6):913‐921. doi:10.1007/s10545-012-9579-6 - DOI - PubMed

Publication types

LinkOut - more resources